News and Events

Photomicrograph of a diffuse large B-cell lymphoma (DLBCL)

Technique targeting cell marker boosts treatment options for B-cell lymphomas

Researchers uncovered the mechanisms behind a drug treatment for diffuse large B-cell lymphoma (DLBCL). The findings help clarify why certain patients respond well to the treatment, while others do not.

Celebrating CCR Careers: Terri Armstrong, Ph.D., ANP-BC

Terri S. Armstrong, Ph.D., ANP-BC, FAAN, FAANP, has more than 30 years of experience caring for people with brain and spine tumors. After almost a decade in the Neuro-Oncology Branch, she is announcing her retirement.

New immunotherapy approach shows potential in some people with metastatic solid tumors, NIH researchers say

Early findings from a small clinical trial provide evidence that a new cellular immunotherapy approach may be effective in treating metastatic colorectal cancer. In the trial, researchers led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, genetically engineered lymphocytes (a type of white blood cell) from each patient to produce receptors that recognize and attack their specific cancer cells. The personalized immunotherapy shrank tumors in several patients and was able to keep the tumors from regrowing for up to 7 months.

Clinical trial researching combination immunotherapy for endometrial cancer

A trial led by Hoyoung M. Maeng, M.D., Associate Research Physician in the Vaccine Branch, is studying the use of combination drug and vaccine therapy for certain patients with HER2-expressing endometrial cancer.

Repairing DNA that breaks during replication

DNA replication can generate double-strand DNA breaks. CCR scientists clarify how these breaks form and how cells repair the potentially catastrophic damage.

Clinical trial researching immunotherapy for prostate cancer

A trial led by Ravi A. Madan, M.D., Senior Clinician in the Genitourinary Malignancies Branch, is studying hormone blocking therapy and immunotherapy for prostate cancer.

Artificial intelligence model analyzes tumor images to predict patients’ response to different cancer therapies

Understanding the genetic makeup of a tumor can help doctors recommend the best treatment option for their patients, but molecular sequencing is costly and not accessible to everyone. A new artificial intelligence model called ENLIGHT DEEP-PT could help overcome these challenges.

Celebrating CCR Careers: Jonathan D. Ashwell, M.D.

For nearly 40 years at NCI, Jonathan D. Ashwell, M.D., has worked to understand the mechanisms and consequences of intracellular signaling, primarily in T cells, and how these contribute to disease. Now, the Chief of the Laboratory of Immune Cell Biology has announced his retirement.

Researchers use artificial intelligence to tease apart subtypes of glioma

A new machine learning algorithm can dig deep into spectral data of brain tumor tissue to reveal genetic mutations, DNA methylation and even the fat content of gliomas. This research advance could help scientists better classify — and one day better treat — brain cancer.

Chengkai Dai appointed to Senior Investigator at CCR

The CCR community congratulates Chengkai Dai, Ph.D., who has been appointed Senior Investigator in the Mouse Cancer Genetics Program. Dai’s laboratory is a pioneer in the field of proteomic instability of cancer. His ongoing research focuses on the molecular mechanisms through which proteomic instability may affect genomic stability, cell invasion and autophagy, areas which hold promise to unveil new molecular pathways that could be targeted in cancer therapy.

Breadcrumb